Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Accounts Payables (2023 - 2025)

Historic Accounts Payables for Nuvation Bio (NUVB) over the last 3 years, with Q3 2025 value amounting to $15.4 million.

  • Nuvation Bio's Accounts Payables rose 2407.11% to $15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.4 million, marking a year-over-year increase of 2407.11%. This contributed to the annual value of $6.3 million for FY2024, which is 18736.99% up from last year.
  • As of Q3 2025, Nuvation Bio's Accounts Payables stood at $15.4 million, which was up 2407.11% from $22.4 million recorded in Q2 2025.
  • In the past 5 years, Nuvation Bio's Accounts Payables registered a high of $22.4 million during Q2 2025, and its lowest value of $2.2 million during Q4 2023.
  • Moreover, its 3-year median value for Accounts Payables was $5.2 million (2024), whereas its average is $7.7 million.
  • The largest annual percentage gain for Nuvation Bio's Accounts Payables in the last 5 years was 42170.25% (2024), contrasted with its biggest fall of 1728.35% (2024).
  • Quarter analysis of 3 years shows Nuvation Bio's Accounts Payables stood at $2.2 million in 2023, then skyrocketed by 187.37% to $6.3 million in 2024, then surged by 141.97% to $15.4 million in 2025.
  • Its last three reported values are $15.4 million in Q3 2025, $22.4 million for Q2 2025, and $10.5 million during Q1 2025.